Instrumento Inactivo

Otros idiomas GRI Bio, Inc.

Acciones

GRI

US3622AW2059

Tiempo real estimado Cboe BZX Otros sitios de cotización 18:22:16 21/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,415 ^USD	+3,57 %		+2,72 %	-85,13 %

10/05	GRI Bio, Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
16/04	GRI Bio amplía la protección de la propiedad intelectual de sus moduladores de células T asesinas naturales (NKT) patentados con la concesión de una patente en Corea	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

GRI Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T Cell Modulators with Issuance of Korea Patent	16/04
GRI Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
GRI Bio, Inc. Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom	04/03
GRI Bio's Board Approves 1-for-7 Reverse Stock Split to Regain Nasdaq Compliance	26/01
GRI Bio Announces Reverse Stock Split	26/01
GRI Bio begins patent enrollment for Phase 2a study of GRI-0621 for IPF treatment	06/12
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)	05/12
GRI Bio, Inc. Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for Treatment of Idiopathic Pulmonary Fibrosis	05/12
GRI Bio Secures FDA Clearance for Investigational New Drug Application for Pulmonary Fibrosis Treatment	27/11
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)	27/11
GRI Bio, Inc. Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis	27/11
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update	15/11
GRI Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases	31/10/23
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference	19/10/23
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression	17/10/23
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference	11/10/23
GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions	05/10/23
Top Premarket Gainers	15/09/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas GRI Bio, Inc.

Acciones

GRI

US3622AW2059

Otros idiomas

Filtros